Results 271 to 280 of about 260,030 (390)

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

, 2008
Jenifer L. Marks, Stephen Broderick, Qin Zhou, Dhananjay Chitale, Allan R. Li, Maureen F. Zakowski, Mark G. Kris, Valerie W. Rusch, Christopher G. Azzoli, Venkatraman Seshan, Marc Ladanyi, William Pao   +11 more
openalex   +1 more source

Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor [PDF]

, 2009
Mats Jönsson, Anna Isinger-Ekstrand, Thomas Edekling, Jakob Eberhard, Dorthe Grabau, David Borg, Mef Nilbert   +6 more
openalex   +1 more source

Protein glycosylation in lung cancer from a mass spectrometry perspective

Mass Spectrometry Reviews, EarlyView.
Abstract Lung cancer is a severe disease for which better diagnostic and therapeutic approaches are urgently needed. Increasing evidence implies that aberrant protein glycosylation plays a crucial role in the pathogenesis and progression of lung cancer.
Mirjam Balbisi, Simon Sugár, Lilla Turiák   +2 more
wiley   +1 more source

Prognostic Impact of <i>KRAS</i> and <i>SMARCA4</i> Mutations and Co-Mutations on Survival in Non-Small Cell Lung Cancer: Insights from the AACR GENIE BPC Dataset. [PDF]

Biomedicines
Manolakos P, Wang YB, Withycombe J, Boccuto L, Ivankovic D.   +4 more
europepmc   +1 more source

An Integrative Drug‐Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations

Molecular Carcinogenesis, EarlyView.
ABSTRACT MYC is among the most frequently dysregulated oncogenes in human cancer, yet its direct targeting remains a significant challenge. Here, we present an in‐silico integrative screening approach to identify compounds and combinations that can block MYC's oncogenic function by specifically disrupting its transcriptional regulatory function.
Anthony Aceto, Yue Wang, Da Yang
wiley   +1 more source

A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors. [PDF]

Anal Chem
Absar F, Novy B, Nagy E, Petrotchenko EV, Popov KI, Cross JB, Thapar R, Borchers CH.   +7 more
europepmc   +1 more source

Protein hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: implications for transcription [PDF]

, 2009
Manikandan Paramasivam, Alexandro Membrino, Susanna Cogoi, Hirokazu Fukuda, Hitoshi Nakagama, Luigi E. Xodo   +5 more
openalex   +1 more source

Intratumoral Nerve Phased Development: A Promising Therapeutic Target

Medicine Bulletin, EarlyView.
ABSTRACT The nervous system has emerged as a critical regulator of tumor biology, engaging in dynamic crosstalk with cancer cells. Although the protumorigenic role of innervation is well established, increasing attention is now directed toward reciprocal influences—how tumors actively shape and remodel local nerve networks within the tumor ...
Xiangxian Che, Hang Wang, Han Wang, Yi‐Zhou Jiang   +3 more
wiley   +1 more source

Expression profiling of KRAS and NOXA genes as prospective biomarkers in ovarian carcinoma. [PDF]

Sci Rep
Abdelnaeem K, Dawood RM, Fotouh BE, Ismail A, Abdalla MS, Ramadan SS.   +5 more
europepmc   +1 more source

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer [PDF]

, 2009
Fotios Loupakis, Luca Emanuele Pollina, I. Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone   +19 more
openalex   +1 more source